Drug Development in Dementia

From bench to bedside, drug development is the process of bringing a novel drug to market. As a progressive and irreversible decline in cognition, dementia affects a patient's pre-existing level of functioning, according to its definition. Alzheimer's disease (AD) is the most common cause of the clinical syndrome of dementia. In Alzheimer's disease, drug development is based on pathophysiological theory that is constantly evolving.

  • Discovery & Development
  • Preclinical Research
  • Clinical Development
  • Post-market Monitoring

Related Conference of Drug Development in Dementia

December 04-05, 2023

5th International Conference on Neurologists

Prague, Czech Republic
December 11-12, 2023

5th World Brain Congress

Rome, Italy
February 01-02, 2024

33rd world congress on Neurology and Therapeutics

Dubai, UAE
February 08-09, 2024

4th Annual Dementia Congress

Paris, France
February 08-09, 2024

5th Global Summit on Brain Disorders and Therapeutics

Madrid, Spain
February 08-09, 2024

6th World Depression Congress

Paris, France
March 14-15, 2024

36th World Conference on Neurology

Paris, France
March 18-19, 2024

28th International Conference on Neurology & Neurophysiology

Zurich, Switzerland
April 11-12, 2024

36th World Congress on Neurorehabilitation

Amsterdam, Netherlands
April 11-12, 2024

38th European Neurology Congress

Amsterdam, Netherlands
April 11-12, 2024

36th World Neuroscience and Neurology Conferences

Amsterdam, Netherlands
May 30-31, 2024

2nd International conference on Neuro Surgery

Vienna, Austria
June 13-14, 2024

37th European Neurology Congress 2024

Rome, Italy
June 27-28, 2024

2nd International conference on Dementia

London, UK
August 13-14, 2024

14th Global Alzheimers Summit

Amsterdam, Netherlands

Drug Development in Dementia Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in